These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 24135401)
1. Individualized therapy in multiple myeloma: are we there? Girnius S; Munshi NC Semin Oncol; 2013 Oct; 40(5):567-76. PubMed ID: 24135401 [TBL] [Abstract][Full Text] [Related]
2. Myeloma genetics and genomics: practice implications and future directions. Faiman B Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058 [TBL] [Abstract][Full Text] [Related]
3. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277 [TBL] [Abstract][Full Text] [Related]
4. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712 [TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Sawyer JR Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186 [TBL] [Abstract][Full Text] [Related]
6. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. Marneni N; Chakraborty R Curr Hematol Malig Rep; 2021 Apr; 16(2):148-161. PubMed ID: 33876390 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Paiva B; Corchete LA; Vidriales MB; Puig N; Maiso P; Rodriguez I; Alignani D; Burgos L; Sanchez ML; Barcena P; Echeveste MA; Hernandez MT; García-Sanz R; Ocio EM; Oriol A; Gironella M; Palomera L; De Arriba F; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Lahuerta JJ; Blade J; Orfao A; Mateos MV; San Miguel JF; Blood; 2016 Apr; 127(15):1896-906. PubMed ID: 26755711 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. Stewart AK; Fonseca R J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017 [TBL] [Abstract][Full Text] [Related]
9. Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma. Wang ZL; Liu Y; Zhou YL; Li JL; Sun QY; Wu LX; Wen L; Lai YY; Liu YR; Chang YJ; Shi HX; Liu KY; Huang XJ; Lu J; Ruan GR Eur J Haematol; 2020 Aug; 105(2):185-195. PubMed ID: 32282962 [TBL] [Abstract][Full Text] [Related]
11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933 [TBL] [Abstract][Full Text] [Related]
12. Investigative tools for diagnosis and management. Munshi NC Hematology Am Soc Hematol Educ Program; 2008; ():298-305. PubMed ID: 19074100 [TBL] [Abstract][Full Text] [Related]
13. Established and Novel Prognostic Biomarkers in Multiple Myeloma. Bustoros M; Mouhieddine TH; Detappe A; Ghobrial IM Am Soc Clin Oncol Educ Book; 2017; 37():548-560. PubMed ID: 28561668 [TBL] [Abstract][Full Text] [Related]
14. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320 [TBL] [Abstract][Full Text] [Related]